Why the study?
Beyond their effect on blood pressure, the acute cardiovascular effects and impact of energy drinks on heart rate in children and teenagers had not been evaluated.
Does acute consumption of energy drinks alter heart rhythm and electrocardiographic time intervals in healthy children and teenagers?
Does acute consumption of energy drinks alter heart rhythm and electrocardiographic time intervals in healthy children and teenagers?
Acute consumption of energy drinks in healthy children and teenagers significantly increases supraventricular extrasystoles and lowers mean heart rate.
May increase supraventricular ectopy and lower heart rate in healthy youth; leaves open arrhythmia risk with repeated exposure.
Beyond their effect on blood pressure, the effect of energy drinks on heart rate in children and teenagers has not been evaluated until now. Thus, this study aimed to investigate the acute cardiovascular effects of energy drinks in healthy children and teenagers. Twenty-six children and adolescents (mean age 14.49 years) received a commercially available energy drink (ED) and placebo on two consecutive days based on the maximum caffeine dosage as proposed by the European Food Safety Authority. Heart rhythm and electrocardiographic time intervals were assessed in a prospective, randomized, double-blind, placebo-controlled, crossover clinical study design. ED consumption resulted in a significantly increased number of supraventricular extrasystoles (SVES) compared to the placebo, whereas supraventricular tachycardia or malignant ventricular arrhythmias were not observed. The mean heart rate (HR) was significantly lower following consumption of EDs. In contrast, QTc intervals were not affected by EDs. Being the first of its kind, this trial demonstrates the cardiovascular and rhythmological effects of EDs in minors. Interestingly, EDs were associated with adverse effects on heart rhythm. Whether higher dosages or consumption in children with preexisting conditions may cause potentially harmful disorders was beyond the scope of this pilot study and remains to be determined in future trials. Trial Registration Number (DRKS-ID): DRKS00027580.
No takes yet. Share an insight, caveat, or question.
Mandilaras et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: